Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years

Contributed by: Business Wire

Logo

Tags

Research

Fitness & Nutrition

Clinical Trials

Other Health

Health

Pharmaceutical

General Health

Other Science

Science

Stallergenes Greer

More Like This

FDA Approves U.S. Pediatric Indication Extension for Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Positive CHMP Opinion for the Extension of Indication of Palforzia® for the Treatment of Toddlers With Confirmed Peanut Allergy

Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

Positive Adherence Impact of IPUMP® Connected Assistant for Sublingual Liquid Allergen Immunotherapy Treatment